Organigram Global Inc Revenue Growth Rates (OGI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Organigram Global Inc   (NASDAQ: OGI)
 

OGI's Revenue Growth by Quarter and Year

Organigram Global Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/OGI/growth
https://api.csimarket.com/api/v1/companies/OGI/fundamentals
https://api.csimarket.com/api/v1/companies/OGI/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
OGI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June 76.45
2nd Quarter March 43.60
1st Quarter December 198.53
FY 318.58

OGIs Annual Revenue
Organigram Global Inc 's Revenue in the fiscal year 2025 $ 198.53 millions
Organigram Global Inc 's Revenue in the fiscal year 2024 $ 117.49 millions
Organigram Global Inc 's Revenue in the fiscal year 2023 $ 111.69 millions
Organigram Global Inc 's Revenue in the fiscal year 2022 $ 114.65 millions
Organigram Global Inc 's Revenue in the fiscal year 2021 $ 62.46 millions




OGI Revenue third quarter 2026 Y/Y Growth Comment
Organigram Global Inc achieved in the third quarter 2026, above Company average Revenue rise of 49.43% year on year, to $ 76.45 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 68 other companies have achieved higher Revenue growth. While Organigram Global Inc ' s Revenue jump of 49.43% ranks overall at the positon no. 469 in the third quarter 2026.


OGI Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June 49.43 %
2nd Quarter March -4.64 %
1st Quarter December 62.14 %
FY   -

Financial Statements
Organigram Global Inc 's third quarter 2026 Revenue $ 76.45 millions OGI's Income Statement
Organigram Global Inc 's third quarter 2025 Revenue $ 51.16 millions Quarterly OGI's Income Statement


OGI Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June 75.34 %
2nd Quarter March -78.04 %
1st Quarter December -
FY (Year on Year)   -


Back to OGI Growth rate Comparisons >> Back to OGI Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #69
Healthcare Sector #119
Overall #469

Revenue Y/Y Growth Statistics
High Average Low
70.45 % 12.8 % -100 %
(Aug 31 2022)   (Aug 31 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #69
Healthcare Sector #119
Overall #469
Revenue Y/Y Growth Statistics
High Average Low
70.45 % 12.8 % -100 %
(Aug 31 2022)   (Aug 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Organigram Global Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
273.58 % 2.53 % -100 %
(Sep 30 2024)  


OGI's III. Quarter Q/Q Revenue Comment
Organigram Global Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 75.34%, to $ 76.45 millions, from $43.60 millions in the second quarter.
OGI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Organigram Global Inc 's Revenue growth quarter on quarter, overall rank is 213.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #55
Overall #213
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #55
Overall #213
Revenue Q/Q Growth Statistics
High Average Low
273.58 % 2.53 % -100 %
(Sep 30 2024)  


OGI's III. Quarter Q/Q Revenue Comment
Organigram Global Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 75.34%, to $ 76.45 millions, from $43.60 millions in the second quarter.
OGI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Organigram Global Inc 's Revenue growth quarter on quarter, overall rank is 213.


Organigram Global Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending (Sep 30 2024) 12 Months Ending (Sep 30 2023) 12 Months Ending (Aug 31 2022) 12 Months Ending (Aug 31 2021)
Cumulative Revenue 12 Months Ending $ 198.53
Y / Y Revenue Growth (TTM) 68.98 %
Year on Year Revenue Growth Overall Ranking # 2778
Seqeuential Revenue Change (TTM) 68.98 %
Seq. Revenue Growth (TTM) Overall Ranking # 2778


Cumulative Revenue growth Comment
Organigram Global Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 68.98% year on year, to $ 199 millions if the fiscal year would have ended in Sep 30 2025.
Organigram Global Inc 's trailing twelve months Revenue growth was higher than company's average 26.38% and higher than 5.19% growth in Sep 30 2024.

In the Healthcare sector 394 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. 2778.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 135
Healthcare Sector # 395
Overall # 2778

Revenue TTM Y/Y Growth Statistics
High Average Low
83.56 %
 26.38 %
-3.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 135
Sector # 395
S&P 500 # 2778
Cumulative Revenue growth Comment
Organigram Global Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 68.98% year on year, to $ 199 millions if the fiscal year would have ended in Sep 30 2025.
Organigram Global Inc 's trailing twelve months Revenue growth was higher than company's average 26.38% and higher than 5.19% growth in Sep 30 2024.
The momentum is even more impressive from twelve months ended Sep 30 2024 exhibited at 68.98 % increase from $117.49 millions in the period from Sep 30 2024 to Aug 31 2021.

In the Healthcare sector 394 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. 2778.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 135
Healthcare Sector # 395
Overall # 2778

Revenue TTM Y/Y Growth Statistics
High Average Low
83.56 %
26.38 %
-3.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 135
Sector # 395
S&P 500 # 2778




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OGI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Kiniksa Pharmaceuticals International Plc55.36%$ 55.360 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Escalon Medical Corp 50.22%$ 50.225 millions
Heartflow Inc 49.80%$ 49.801 millions
Organigram Global Inc 49.43%$ 49.432 millions


About Organigram Global Inc Revenue Growth Rates (OGI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Organigram Global Inc (CIK 1620737).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-25-057233
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Organigram Global Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.